{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031252","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.919589+00:00","generated_at":"2026-05-31T09:59:35.532405+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback","bullets":["Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.","G&A expenses $2.4M, down 17% YoY; R&D expenses $4.9M, down 19% YoY.","Ovaprene Phase 3 contraceptive study recruiting at 20 U.S. sites; ~125 women expected to complete 6 months by Q2 2025.","Sildenafil Cream Phase 3 design pending additional FDA feedback; each Phase 3 study estimated at ~$15M.","Total grants received for DARE-LARC1 now ~$29.3M; pipeline includes DARE-HRT1 in development."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031252","json":"https://secwatch.observer/filing/0001493152-24-031252.json","markdown":"https://secwatch.observer/filing/0001493152-24-031252.md","text":"https://secwatch.observer/filing/0001493152-24-031252.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/0001493152-24-031252-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224031252/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:59:35.532405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}